Angiogenesis is a prerequisite for tumor growth and metastasis. Vascular cell adhesion molecule-1 (VCAM-1) is expressed on endothelial cells as a result of vascular endothelial growth factor (VEGF) stimulation.
Purpose
To determine if measurement in serum of VEGF or VCAM-1 provides an accurate measure of tumor angiogenesis.
Methods
VCAM-1 and VEGF were measured in the serum of women with early and advanced breast cancer by ELISA. Levels were compared to levels of VCAM-1 and VEGF in women with normal breasts and levels of the endothelial glycoprotein von Willebrand factor. Levels of VEGF and VCAM-1 in women with early breast cancer were correlated with established clinicopathological prognostic markers and intratumoral microvessel density (IMD).
Results
In early breast cancer serum VCAM-1 correlated closely with the microvessel density in tumors (r=0.61, p<0.001). Women with lymph node-positive and high-grade tumors had higher levels of serum VCAM-1 than women with lymph node-negative and low-grade tumors. Serum VEGF demonstrated no correlation with established prognostic features or IMD. Levels of VCAM-1 and VEGF were raised in women with advanced breast cancer.
Conclusion
Serum VCAM-1 is a surrogate marker of angiogenesis in breast cancer and its measurement may help in the assessment of antiangiogenic drugs currently in phase II trials.
FolkmanJ.Angiogenesis in cancer, vascular, rheumatoid and other disease.Nat Med1995; 1: 27–31.
4.
WeidnerN., FolkmanJ., PozzaF.Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.J Natl Cancer Inst1992; 84: 1875–87.
5.
BosariS., LeeA.K., DeLellisR.A., WileyB.D., HeatleyG.J., SilvermanM.L.Microvessel quantitation and prognosis in invasive breast carcinoma.Hum Pathol1992; 23: 755–61.
6.
WeidnerN., SempleJ.P., WelchW.R., FolkmanJ.Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma.N Engl J Med1991; 324: 1–8.
7.
SimpsonJ.F., AhnC., BattiforaH., EstebanJ.M.Endothelial area as a prognostic indicator for invasive breast carcinoma.Cancer1996; 77: 2077–85.
BanksR.E., GearingA.J., HemingwayI.K., NorfolkD.R., PerrenT.J., SelbyP.J.Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies.Br J Cancer1993; 68: 122–4.
10.
OsbornL., HessionC., TizardR.Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes.Cell1989; 59: 1203–11.
LorenzonP., VecileE., NardonE.Endothelial cell E-and P-selectin and vascular cell adhesion molecule-1 function as signaling receptors.J Cell Biol1998; 142: 1381–91.
13.
PigottR., DillonL.P., HemingwayI.H., GearingA.J.Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells.Biochem Biophys Res Commun1992; 187: 584–9.
14.
SudhoffT., WehmeierA., KlicheK.O.Levels of circulating endothelial adhesion molecules (sE-selectin and sV-CAM-1) in adult patients with acute leukemia.Leukemia1996; 10: 682–6.
MatsudaM., TsukadaN., MiyagiK., YanagisawaN.Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy.J Neuroimmunol1995; 59: 35–40.
17.
BoldtJ., MullerM., HeesenM., NeumannK., HempelmannG.G.Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients.Crit Care Med1996; 24: 385–91.
18.
PepperM.S., FerraraN., OrciL., MontesanoR.Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.Biochem Biophys Res Commun1992; 189: 824–31.
LeungD.W., CachianesG., KuangW.J., GoeddelD.V., FerraraN.Vascular endothelial growth factor is a secreted angiogenic mitogen.Science1989; 246: 1306–9.
21.
BrownL.F., BerseB., JackmanR.W.Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.Hum Pathol1995; 26: 86–91.
22.
YoshijiH., GomezD.E., ShibuyaM., ThorgeirssonU.P.Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.Cancer Res1996; 56: 2013–6.
23.
ObermairA., KuceraE., MayerhoferK.Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival.Int J Cancer1997; 74: 455–8.
24.
GaspariniG., ToiM., GionM.Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.J Natl Cancer Inst1997; 89: 139–47.
25.
RelfM., LeJeuneS., ScottP.A.Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.Cancer Res1997; 57: 963–9.
26.
GuidiA.J., SchnittS.J., FischerL.Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast.Cancer1997; 80: 1945–53.
27.
ToiM., KondoS., SuzukiH.Quantitative analysis of vascular endothelial growth factor in primary breast cancer.Cancer1996; 77: 1101–6.
28.
DirixL.Y., VermeulenP.B., PawinskiA.Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.Br J Cancer1997; 76: 238–43.
29.
KondoS., AsanoM., MatsuoK., OhmoriI., SuzukiH.Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients.Biochim Biophys Acta1994; 1221: 211–4.
30.
FerrariG., ScagliottiG.V.Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients [letter].Eur J Cancer1996; 32A: 2368–9.
31.
TakanoS., YoshiiY., KondoS.Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.Cancer Res1996; 56: 2185–90.
32.
GralnickH.R.von Willebrand factor, integrins, and platelets: their role in cancer.J Lab Clin Med1992; 119: 444–7.
33.
DanilovaA.B., PapaianL.P., OkulovV.B.Changes of Willebrand factor level in blood plasma of cancer patients and its role in hemostatic disturbances.Vopr Onkol1996; 42: 26–30.
34.
HaywardJ.L., CarboneP.P., HeusonJ.C., KumaokaS., SegaloffA., RubensR.D.Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.Cancer1977; 39: 1289–94.
BlannA.D.von Willebrand factor antigen: a radial immunodiffusion method evaluated and compared with an Elisa method.Med Lab Sci1992; 49: 141–3.
37.
ChalkleyH.Method for quantitation morphological analysis of tissues.J Natl Cancer Inst1943; 4: 47–53.
38.
VermeulenP.B., GaspariniG., FoxS.B.Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation.Eur J Cancer1996; 32A: 2474–84.
39.
HeerK., KumarH., SpeirsV.Vascular endothelial growth factor in premenopausal women – indicator of the best time for breast cancer surgery?Br J Cancer1998; 78: 1203–7.
40.
FolkmanJ.What is the evidence that tumors are angiogenesis dependent? [editorial].J Natl Cancer Inst1990; 82: 4–6.
41.
KochA.E., HalloranM.M., HaskellC.J., ShahM.R., PolveriniP.J.Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1.Nature1995; 376: 517–9.
VelikovaG., BanksR.E., GearingA.Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer.Br J Cancer1997; 76: 1398–404.
44.
EskelinenM., KatajaV., HamalainenE., KosmaV.M., PenttilaI., AlhavaE.Serum tumour markers CEA, AFP, CA 15–3, TPS and Neu in diagnosis of breast cancer.Anticancer Res1997; 17: 1231–4.
